Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?
12:37pm, Thursday, 29'th May 2025
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte to Present at Upcoming Investor Conference
08:00am, Tuesday, 27'th May 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs Healthcare Conference on Monday, June 9, 2025 at 11:20 am (ET). The presentation will
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
11:55am, Friday, 16'th May 2025
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 07'th May 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript
12:53pm, Tuesday, 29'th Apr 2025
Incyte Corporation (NASDAQ:INCY ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Greg Shertzer - Director of Investor Relations Herve Hoppenot - Chief Executive Office
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
12:05pm, Tuesday, 29'th Apr 2025
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings
10:35am, Tuesday, 29'th Apr 2025
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Incyte (INCY) Q1 Earnings and Revenues Top Estimates
09:15am, Tuesday, 29'th Apr 2025
Incyte (INCY) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.64 per share a year ago.
Incyte raises 2025 sales forecast for blood cancer drug after solid quarter
09:03am, Tuesday, 29'th Apr 2025
Incyte Corp raised its annual sales forecast for its blood cancer treatment Jakafi on Tuesday, after robust sales of the drug helped it beat Wall Street estimates for quarterly results.
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
07:00am, Tuesday, 29'th Apr 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs.
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
08:00am, Friday, 25'th Apr 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AACR25--Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025.
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know
08:50am, Wednesday, 23'rd Apr 2025
INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Tuesday, 22'nd Apr 2025
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 07'th Apr 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
